The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
Ask the Experts About

Workplace and Insurance IssuesWorkplace and Insurance Issues
Rollover images to visit our other forums!
  • Email Email
  • Glossary Glossary

Patent issue and FTA, big problem for poor positives.
Feb 3, 2012

Hi Jacques, if we assume that EU wins the debate of FTA and indian generics lose the right to copy drugs, which anti HIV molecules are going to be within and out of the patent issue? zidovudine, lamivudine, nevirapine etc are pretty much older in the field and should be spared from the issue of patent. in that case medicines like duovir -N / triomune 30 should be kept on being produced by indian generics and HAART like viraday (generic of atripla) is going to be banned, as well as new molecules like darunavir, raltegravir etc? Generally how long does it take for a molecule to cross its patent period and can you please post a list of HAART MOLECULES BASED ON THIS PATENT EXPIRY? Regards.

Response from Mr. Chambers

I appreciate your follow-up question, but I'm not the one to be able to answer that. I have no substantial medical training and really need to stick to questions regarding benefits, insurance, and workplace issues.

Perhaps one of the doctors on this panel might be able to answer you question.

Good luck, Jacques

EU-India FTA
I am at risk?

  • Email Email
  • Glossary Glossary



This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint